ClinicalTrials.gg
CompletedNCT00452452Updated Aug 15, 2012Results posted

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 9 sites in Poland. Open to participants aged 7 Months to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-15.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
355
Allocation
Non-randomized
Ages
7 Months to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
21st of 44
355 · median 328
Started
2007
with 5 others
Phase 3
19 of 44
none open now
Registered
3rd of 44
by date
Lead sponsor
4 of 44
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 21st largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 3rd registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 7 Months to 5 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent Pneumococcal conjugate vaccine (13vPnC) in older infants and children who have not previously been immunized with Pneumococcal vaccine.

03

Conditions studied

  • Pneumococcal Infections

Keywords

  • Pneumococcal Vaccines
04

Who can participate

Ages eligible
7 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged from 7 months to \<72 months at time of enrollment.
  2. Available for entire study period and whose parent/legal guardian could be reached by telephone.
  3. Healthy as determined by medical history, physical examination, and judgment of the investigator.
  4. Parent/legal guardian had to be able to complete all relevant study procedures during subject participation.

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with licensed or pneumococcal vaccine.
  2. A previous anaphylactic reaction to any vaccine or vaccine-related component.
  3. to vaccination with pneumococcal vaccine.
  4. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  5. Known or suspected immune deficiency or suppression.
  6. History of culture-proven invasive disease caused by S pneumoniae.
  7. Major known congenital malformation or serious chronic disorders.
  8. Significant neurological disorder or history of seizure including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Does not include resolving syndromes due to birth trauma such as Erb palsy.
  9. Receipt of blood products or gamma-globulin (including monoclonal antibodies) in the last 3 months.
  10. Participation in another investigational or interventional trial. Participation in purely observational studies is acceptable.
  11. Child is a direct descendant (child or grandchild) of a member of the study site personnel.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
355 participants (actual)

Study arms

  • Experimental
    A

    Biological: 13-valent Pneumococcal Conjugate Vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination

    Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: 28 to 42 days after vaccination 3 for Group 1 (13 to <17 months of age), after vaccination 2 for Group 2 (14 to <26 months of age), and after vaccination 1 for Group 3 (26 to <73 months of age).

  2. Geometric Mean Antibody Concentration (GMC) After Vaccination in 13vPnC Groups

    GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: 28 to 42 days after vaccination 3 for Group 1 (13 to <17 months of age), after vaccination 2 for Group 2 (14 to <26 months of age), and after vaccination 1 for Group 3 (26 to <73 months of age).

Secondary outcomes

  1. Percentage of Participants Reporting Pre-Specified Local Reactions

    Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  2. Percentage of Participants Reporting Pre-Specified Systemic Events

    Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

07

Results

Posted Aug 15, 2012

Participant flow

Participants were recruited in Poland from July 2007 to September 2007.

Participant flow — Overall Study
Milestone13vPnC 7 to <12 Months of Age13vPnC 12 to <24 Months of Age13vPnC 24 to < 72 Months of Age
Started90112153
Vaccinated dose 190112152
Vaccinated dose 2901120
Vaccinated dose 38900
Completed88112152
Not completed201
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject100
Withdrew: Lost to follow-up100

Outcome measures

PrimaryPercentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination

Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
28 to 42 days after vaccination 3 for Group 1 (13 to <17 months of age), after vaccination 2 for Group 2 (14 to <26 months of age), and after vaccination 1 for Group 3 (26 to <73 months of age).
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination
percentage of participants13vPnC 7 to <12 Months of Age13vPnC 12 to <24 Months of Age13vPnC 24 to < 72 Months of Age
Common Serotypes - Serotype 4 (n= 84,110,151)100.0 (95.7 to 100.0)100.0 (96.7 to 100.0)99.3 (96.4 to 100.0)
Common Serotypes - Serotype 6B (n=83,110,150)98.8 (93.5 to 100.0)100.0 (96.7 to 100.0)99.3 (96.3 to 100.0)
Common Serotypes - Serotype 9V (n= 83,104,148)98.8 (93.5 to 100.0)99.0 (94.8 to 100.0)98.6 (95.2 to 99.8)
Common Serotypes - Serotype 14 (n= 84,108,135)100.0 (95.7 to 100.0)100.0 (96.6 to 100.0)88.1 (81.5 to 93.1)
Common Serotypes - Serotype 18C (n= 83,109,151)100.0 (95.7 to 100.0)100.0 (96.7 to 100.0)98.7 (95.3 to 99.8)
Common Serotypes - Serotype 19F (n=84,110,147)97.6 (91.7 to 99.7)100.0 (96.7 to 100.0)98.0 (94.2 to 99.6)
Common Serotypes - Serotype 23F (n= 84,110,151)98.8 (93.5 to 100.0)92.7 (86.2 to 96.8)93.4 (88.2 to 96.8)
Additional Serotypes - Serotype 1 (n= 83,108,149)100.0 (95.7 to 100.0)100.0 (96.6 to 100.0)96.6 (92.3 to 98.9)
Additional Serotypes - Serotype 3 (n= 83,108,149)98.8 (93.5 to 100.0)100.0 (96.6 to 100.0)97.3 (93.3 to 99.3)
Additional Serotypes - Serotype 5 (n= 84,107,152)97.6 (91.7 to 99.7)99.1 (94.9 to 100.0)98.7 (95.3 to 99.8)
Additional Serotypes - Serotype 6A (n= 84,110,150)100.0 (95.7 to 100.0)98.2 (93.6 to 99.8)100.0 (97.6 to 100.0)
Additional Serotypes - Serotype 7F (n= 84,108,142)100.0 (95.7 to 100.0)100.0 (96.6 to 100.0)99.3 (96.1 to 100.0)
Additional Serotypes - Serotype 19A (n=84,110,150100.0 (95.7 to 100.0)100.0 (96.7 to 100.0)100.0 (97.6 to 100.0)
SecondaryPercentage of Participants Reporting Pre-Specified Local Reactions

Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions
percentage of participants13vPnC Group 1 - Dose 113vPnC Group 2 - Dose 113vPnC Group 3 - Dose 113vPnC Group 1 - Dose 213vPnC Group 2 - Dose 213vPnC Group 1 - Dose 3
Tenderness - Any15.133.342.315.143.715.2
Tenderness - Significant1.20.04.13.54.16.4
Swelling - Any36.044.536.932.241.025.0
Swelling - Mild32.636.728.228.736.220.5
Swelling - Moderate11.624.820.314.012.111.3
Swelling - Severe0.00.00.00.00.00.0
Redness - Any48.870.050.046.054.737.8
Redness - Mild41.955.537.440.244.731.3
Redness - Moderate16.338.225.79.325.512.5
Redness - Severe0.00.00.00.00.00.0
SecondaryPercentage of Participants Reporting Pre-Specified Systemic Events

Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events
percentage of participants13vPnC Group 1 - Dose 113vPnC Group 2 - Dose 113vPnC Group 3 - Dose 113vPnC Group 1 - Dose 213vPnC Group 2 - Dose 213vPnC Group 1 - Dose 3
Fever ≥38°C but ≤39°C3.43.70.78.15.15.1
Fever >39°C but ≤40°C1.20.90.72.30.01.3
Fever >40°C0.00.00.00.00.00.0
Decreased appetite19.522.216.317.225.517.5
Irritability24.130.614.334.534.024.7
Increased sleep9.213.011.69.310.12.6
Decreased sleep24.119.46.818.420.415.0
Use of antipyretic medication to treat symptoms9.210.12.79.313.37.6
Use of antipyretic medication to prevent symptoms8.013.84.84.714.35.1
PrimaryGeometric Mean Antibody Concentration (GMC) After Vaccination in 13vPnC Groups

GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
28 to 42 days after vaccination 3 for Group 1 (13 to <17 months of age), after vaccination 2 for Group 2 (14 to <26 months of age), and after vaccination 1 for Group 3 (26 to <73 months of age).
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration (GMC) After Vaccination in 13vPnC Groups
μg/mL13vPnC 7 to <12 Months of Age13vPnC 12 to <24 Months of Age13vPnC 24 to < 72 Months of Age
Common Serotypes - Serotype 43.63 (3.11 to 4.23)4.28 (3.78 to 4.86)3.37 (2.95 to 3.85)
Common Serotypes - Serotype 6B4.77 (3.90 to 5.84)3.38 (2.81 to 4.06)3.41 (2.80 to 4.16)
Common Serotypes - Serotype 9V2.56 (2.21 to 2.96)3.08 (2.69 to 3.53)2.67 (2.32 to 3.07)
Common Serotypes - Serotype 148.04 (6.95 to 9.30)6.45 (5.48 to 7.59)2.24 (1.71 to 2.93)
Common Serotypes - Serotype 18C2.77 (2.39 to 3.23)3.71 (3.29 to 4.19)2.56 (2.17 to 3.03)
Common Serotypes - Serotype 19F2.88 (2.35 to 3.54)3.07 (2.68 to 3.51)2.53 (2.14 to 2.99)
Common Serotypes - Serotype 23F2.16 (1.82 to 2.55)1.98 (1.64 to 2.39)1.55 (1.31 to 1.85)
Additional Serotypes - Serotype 12.88 (2.44 to 3.39)2.74 (2.37 to 3.16)1.78 (1.52 to 2.08)
Additional Serotypes - Serotype 31.94 (1.68 to 2.24)1.86 (1.60 to 2.15)1.42 (1.23 to 1.64)
Additional Serotypes - Serotype 52.85 (2.34 to 3.46)2.16 (1.89 to 2.47)2.33 (2.05 to 2.64)
Additional Serotypes - Serotype 6A3.72 (3.12 to 4.45)2.62 (2.25 to 3.06)2.96 (2.52 to 3.47)
Additional Serotypes - Serotype 7F5.30 (4.54 to 6.18)5.99 (5.40 to 6.65)4.92 (4.26 to 5.68)
Additional Serotypes - Serotype 19A4.77 (4.28 to 5.33)4.94 (4.31 to 5.65)6.03 (5.22 to 6.97)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC 7 to <12 Months of Age—5/90 (5.6%)55/90 (61.1%)
13vPnC 12 to <24 Months of Age—2/112 (1.8%)77/112 (68.8%)
13vPnC 24 to < 72 Months of Age—2/152 (1.3%)74/152 (48.7%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
Event13vPnC 7 to <12 Months of Age13vPnC 12 to <24 Months of Age13vPnC 24 to < 72 Months of Age
DiarrhoeaGeneral disorders1/900/1120/152
Exanthema subitumInfections and infestations1/900/1120/152
Febrile convulsionNervous system disorders1/900/1120/152
Gastrointestinal infectionInfections and infestations1/900/1120/152
PneumoniaInfections and infestations1/900/1120/152
Thermal burnInjury, poisoning and procedural complications1/900/1120/152
Otitis mediaInfections and infestations0/901/1120/152
PharyngitisInfections and infestations0/901/1121/152
StomatitisGastrointestinal disorders0/901/1120/152
VomitingGastrointestinal disorders0/901/1120/152
Most frequent other events
Showing 10 of 95
Most frequent other events
Event13vPnC 7 to <12 Months of Age13vPnC 12 to <24 Months of Age13vPnC 24 to < 72 Months of Age
Erythema (any)Skin and subcutaneous tissue disorders42/8677/11074/148
Erythema (Mild)Skin and subcutaneous tissue disorders36/8661/11055/147
Erythema (any)Skin and subcutaneous tissue disorders40/8758/106—
Erythema (Mild)Skin and subcutaneous tissue disorders35/8746/103—
Induration (Any)Skin and subcutaneous tissue disorders31/8649/11055/149
Tenderness (any)Skin and subcutaneous tissue disorders13/8645/103—
Tenderness (any)Skin and subcutaneous tissue disorders13/8636/10863/149
Induration (Any)Skin and subcutaneous tissue disorders28/8743/105—
Erythema (Moderate)Skin and subcutaneous tissue disorders14/8642/11038/148
Erythema (any)Skin and subcutaneous tissue disorders31/82——

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC 7 to <12 Months of Age13vPnC 12 to <24 Months of Age13vPnC 24 to < 72 Months of AgeTotal
Mean8.7 ± 1.617.6 ± 3.542.0 ± 13.125.9 ± 17.0
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC 7 to <12 Months of Age13vPnC 12 to <24 Months of Age13vPnC 24 to < 72 Months of AgeTotal
Female475874179
Male435479176
08

Study locations

9 sites
  • Bydgoszcz, 85-168, Poland
  • Bydgoszcz, 85-316, Poland
  • Debica, 39-200, Poland
  • Krakow, 31-503, Poland
  • Leczna, 21-010, Poland
  • Lodz, 91-738, Poland
  • Oborniki Salskie, 55-120, Poland
  • Proznan, 61-709, Poland
  • Trzebnica, 55-100, Poland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 4 years 5 months after primary completion. A results delay was requested in Jan 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2007
First posted
Mar 27, 2007
Start
Jul 2007
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results delay requested
Jan 21, 2009
Results first posted
Aug 15, 2012
Last update
Aug 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00452452
Responsible party
Sponsor
First posted
Mar 27, 2007
Start date
Jul 2007
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Aug 15, 2012
Last update
Aug 15, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Poland: WPWZMED@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion